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Abstract: Background: The cytochrome P450 drug metabolizing enzymes CYP2D6 and CYP2C19 are
the major targets for pharmacogenomics (PGx) testing and determining for drug response. Clinical
dosing guidelines for specific drug-gene interactions (DGI) are publicly available through PharmGKB.
The aim of this register study was to map the use of drugs in Denmark for drugs having actionable
dosing guidelines (AG) i.e., dosing recommendations different from standard dosing for CYP2D6
or CYP2C19 DGI in terms of consumption. Methods: The Danish Register of Medicinal Product
Statistics was the source to retrieve consumption in Defined Daily Dose (DDD) i.e., the assumed
average maintenance dose per day for a drug used for its main indication in adults and number of
users (2017 data). Clinical dosing guidelines were available from the PharmGKB website. Results:
Forty-nine drugs have guidelines corresponding to 14.5% of total sales in DDD. Twenty-eight drugs
have AG corresponding to 375.2 million DDD. Pantoprazole, lansoprazole, omeprazole, clopidogrel,
and metoprolol constituted fifty-eight percent of the consumption in DDD of drugs having AG. The
consumption of antidepressant drugs, opioids, and antipsychotic drugs were 157.0 million DDD;
with 441,850 users, 48.9 million DDD; with 427,765 users, and 23.7 million DDD; with 128,935 users,
respectively. Age distributions of consumption of drugs and drug combinations, e.g., for sertraline
redeemed either alone or in combination with metoprolol and tramadol, are presented. Conclusion:
This exploratory register study clearly showed that a large fraction of the Danish population, especially
the elderly, are exposed to drugs or drug combinations for which there exist AG related to PGx of
CYP2D6 or CYP2C19.
Keywords: drug consumption; pharmacogenomics; cytochrome P450; polypharmacy;
pharmacogenomics testing; drug-drug interactions; drug–gene interaction
1. Introduction
Cytochromes P450 (CYP450) drug metabolizing enzymes are the major enzymes in catalyzing the
oxidative biotransformation of 70%–80% of all drugs in clinical use to either inactive metabolites or
active substances [1,2]. The polymorphism of genes encoding the CYP450 family of enzymes, and
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in particular CYP2D6 and CYP2C19, has attracted considerable attention as the major targets for
pharmacogenomics (PGx) testing since they are highly polymorphic and thereby determining for drug
response and adverse drug reactions (ADR) [3–5]. The Clinical Pharmacogenetics Implementation
Consortium (CPIC) [6] and the Dutch Pharmacogenetics Working Group (DPWG) [7,8] both provide
widely recognized clinical dosing guidelines for specific drug-gene interactions (DGI) [9,10]. These
are compiled and publically available through the Pharmacogenomics Knowledgebase (PharmGKB;
https://www.pharmgkb.org) [11]. Based on drug-gene scores for metabolic activity [12–14] DGI
are classified into five distinct phenotypes defined as; “poor metabolizers” (PM), “intermediate
metabolizers” (IM), “extensive metabolizers” (EM; normal activity) and “rapid and ultra-rapid
metabolizers” (RM and UM) with UM having faster metabolic activity than RM. We will use the
term RM covering both RM and UM throughout this manuscript. The guidelines provide, based on
phenotype score, clinical recommendations such as dose adjustment, dose monitoring or avoidance of
the given drugs. The FDA also recognizes the importance of DGI and has annotated a large number of
drugs with considerations and actions to be taken from a PGx perspective [11].
The term phenoconversion introduces a complicating factor, which potentially can give rise to
“genotype-phenotype” mismatches; a person scored as an EM or RM can be phenoconverted to a PM
by co-medications [15] (drug–drug interactions). This means that the “true” number of PMs could be
significantly higher compared to the number of PMs measured by PGx-testing alone. This term also
refers to drug–drug–gene interactions (DDGI) [16]. That phenoconversion could alter a person’s drug
metabolizing status has been shown in polypharmacy patients [17–19] and a recent comprehensive
review underscores the importance of assessing and accounting for DGI and DDGI [4]. The guidelines
provided by the PharmGKB webpage does not incorporate drug-drug interactions (DDI/DDGI) in the
assessment of dose adjustments. However, the issue is recognized and initiatives have been taken to
incorporate DDI/DGI in clinical decision tools e.g., youScript® [19,20] which integrates PGx testing with
comprehensive drug–gene and drug–drug interaction information to assess the cumulative impact of a
patient’s genetics and drug regimen, and their risk for adverse drug events. In spite of many initiatives
and advances in PGx implementation, significant barriers remain to use PGx-tests proactively; this
includes improvement of physician’s and pharmacist´s awareness and understanding about PGx
as well as convincing evidence presenting the collective clinical utility of a panel of PGx-markers
in medication optimization [21]. A Health Technology Assessment report published in 2012 by the
Danish Health Authority focusing on the potential use of CYP2D6 and CYP2C19 genotyping as a tool
to improve antipsychotic drug treatment concluded that genotyping has the potential. However, the
significant organizational hurdles and lack of evidence of PGx-tests utility as a tool for improving the
antipsychotic treatment were barriers for daily routine use [22,23].
The aim of this register study was to map the use of drugs in Denmark by applying Anatomical
Therapeutic Chemical (ATC) codes [24], for drugs having dosing guidelines (CPIC or DPWG) for
CYP2D6 and/or CYP2C19, in terms of consumption of Defined Daily Dose (DDD) [24]. I.e., the assumed
average maintenance dose per day for a drug used for its main indication in adults, and number of users
who redeemed the drugs during 2017. In addition, consumption of inappropriate drug combinations,
according to Medscape® drug interaction checker [25], redeemed to users on the same day or during
2017 are given and discussed in relation to DDI/DDGI. We hope by this study to show the widespread
use of drugs having PGx-based clinical dosing guidelines in order to identify areas where PGx testing
could be a supporting tool in clinical decision making such as polypharmacy patients. This study
present data retrieved from The Danish Register of Medicinal Product Statistics [26].
2. Materials and Methods
2.1. Clinical Dosing Guidelines
The Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch
Pharmacogenetics Working Group (DPWG) clinical dosing guidelines for specific gene-drug pairs were
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used as the source. The guidelines are available through the publicly available PharmGKB homepage
(https://www.pharmgkb.org/). By using the PharmGKB website all drugs redeemed in Denmark
during 2017, having a CPIC or DPWG guideline for CYP2D6 and/or CYP2C19 drug-gene pairs, were
mapped according to their ATC codes [24]. Drugs with guidelines were divided into drugs having an
actionable guideline (AG) defined as at least one clinical recommendation (i.e., dose adjustment, dose
monitoring, or avoidance of the given drug) different from the EM (normal situation) of any of the
phenotypes PM, IM, or RM. Drugs having non-actionable guidelines (N-AG) were defined as drugs
with no clinical recommendation different from EM of any of the phenotypes based on current clinical
knowledge. N-AG are only provided by DPWG. In depth analyses of consumption were applied
within ATC codes N02A (opioids), N05A (antipsychotics), and N06A (antidepressants) due to the
relative large number of guidelines existing within these therapeutic groups. Assignment of FDA
annotations were gathered from the FDA’s “Table of Pharmacogenomic Biomarkers in Drug Labels”
for CYP2D6 and CYP2C19 [11,27]. “Actionable PGx” contains information about changes in efficacy,
dosage, metabolism, or toxicity due DGI (e.g., “poor metabolizers”) relating to these two CYP-enzymes.
2.2. Register Data
The Danish Register of Medicinal Product Statistics [26], that comprises records of all prescriptions
redeemed since 1st of January 1996, were used to retrieve drug consumption in 2017 by using
Medstat.dk [26]. Consumption, identifiable with a person, is expressed as defined daily dose
(DDD) [24] and number of users who redeemed prescriptions of the drugs searched for as shown in
Tables 1–3 and Figure 1. Over the counter (OTC) consumption is not identifiable with a person and
therfore is not part of this study. Data given for drug combinations redeemed to the same person, as
shown in Tables 4 and 5, were retrieved by using the personal identification number [28] (the CPR
number), a unique identifier to all Danish inhabitants since 1968, to link the number of users who
redeemed the combination of drugs shown on the same day or during 2017. In addition, Table 5 also
present data on age distribution of comsumption. These data are not publically available and were
provided from the same register as above by Statistics Denmark [29] upon request. This also explains
the minor differences seen in numbers in Table 4 compared to Tables 1–3. Data provided by Statistic
Denmark were retrieved at another time compared to Tables 1–3 and thereby small adjustments of
data have occurred. For conversion to prevalence (users/1000 inhabitants), the total Danish population
in 2017 was 5.748.769 (https://www.statistikbanken.dk/statbank5a/default.asp?w=1920). Drug-drug
interactions were scored in severity by using Medscape® drug interaction checker [25] and warnings
related to CYP2D6 and/or CYP2C19 are displayed as “monitor closely” or “serious use alternate”.
The dosing information, length of treatment and indication for prescribing were not recorded and
ethics approval was not applicable according to Danish law, since the use of anonymized healthcare
data for pharmacoepidemiological research does not require subject consent or approval from the
Ethics Committee.
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Table 1. Consumption of antidepressants.
Antidepressants ATC-Code CYP2D6 CYP2C19 FDAAnn.
Consumption
(Users)
Consumption
(DDD) (×1000)
Total antidepressants N06A 414,850 156,968
Sertraline 1 N06AB06 - AG - 100,925 43,690 (27.8)
Citalopram N06AB04 - AG A 100,125 34,554 (22.0)
Venlafaxine N06AX16 AG - A 50,155 22,757 (14.5)
Mirtazapine N06AX11 NG NG - 82,300 15,637 (10.0)
Escitalopram N06AB10 - AG A 24,020 9259 (5.9)
Duloxetine 1 N06AX21 NG - A 30,500 8613 (5.4)
Paroxetine 1 N06AB05 AG - I 12,935 4960 (3.1)
Fluoxetine 1,2 N06AB03 NG NG I 10,815 4207 (2.7)
Amitriptyline N06AA09 AG AG A 35,020 3625 (2.3)
Nortriptyline N06AA10 AG A 14,965 3222 (2.1)
Agomelatine N06AX22 - - 5370 1827 (1.1)
Vortioxetine N06AX26 - - A 5700 1601 (1.0)
Mianserin N06AX03 - - - 12,070 1081 (<1)
Clomipramine 1 N06AA04 AG AG A 2775 745 (<1)
Imipramine N06AA02 AG AG A 4085 441 (<1)
Isocarboxazid N06AF01 - - - 380 227 (<1)
Bupropion 1 N06AX12 - - - 2005 149 (<1)
Doxepin 1 N06AA12 AG AG A 485 99 (<1)
Dosulepin N06AA16 - - - 405 92 (<1)
Reboxetine N06AX18 - - 375 79 (<1)
Fluvoxamine 2 N06AB08 AG - A 185 57 (<1)
Moclobemide N06AG02 - NG - 120 44 (<1)
Maprotiline N06AA21 - - - 20 3 (<1)
The table is sorted in order of increasing consumption. AG: actionable guideline, N-AG: non-actionable guideline,
and -: no guideline. FDA annotation (FDA ann.) related to CYP2D6 and/or CYP2C19. Numbers in brackets are
percentage expressed relative to the total consumption of antidepressants in DDD: A = action, I = informative;
T-req = test required. DDD: Defined Daily Dose (DDD). 1 Inhibitor of CYP2D6 and 2 inhibitor CYP2C19 [30].
Table 2. Consumption of analgesics.
Analgesics ATC Code CYP2D6 CYP2C19 FDAAnn.
Consumption
(Users)
Consumption
(DDD) (×1000)
Total analgesics N02 1,231,305 196,593
Total opioids N02A 427,765 44,50848,875 * (24.8)
Tramadol N02AX02 AG A 265,030 20,520 (42.0)
Morphine N02AA01 97,765 5698 (11.7)
Codeine &
acetylsalicylic acid) N02AJ07 20,980 5536 (11.3)
Oxycodone N02AA05 NG 69,470 4416 (9.0)
Codeine * R05DA04 AG A 71,135 4367 (8.9)
Codeine &
paracetamol ** N02AJ06 (AG) (A) 24,210 3209 (6.6)
Fentanyl N02AB03 18,815 3046 (6.2)
Buprenorphine N02AE01 17,470 1132 (2.3)
Ketobemidone and
antispasmodics N02AG02 6085 419 (<1)
Tapentadol N02AX06 2110 302 (<1)
Hydromorphone N02AA03 85 124 (<1)
See Table 1 for legend. * Codeine (R05DA04) is included in the total consumption of opioids in DDD (44,508 +
4367 = 48,875 (1000)). Numbers in brackets are percentage expressed relative to total consumption of opioids incl.
codeine in DDD. ** Since codeine is approximately 25 mg in N02AJ06, opposite N02AJ07 where the content is three
times less, the term AG was applied. Drugs or drug combinations with a consumption of less of 100,000 DDD are
not shown.
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Table 3. Consumption of antipsychotics.
Antipsychotics ATC Code CYP2D6 CYP2C19 FDAAnn.
Consumption
(Users)
Consumption
(DDD) (×1000)
Total antipsychotics N05A 128,935 23,705
Quetiapine N05AH04 NG - - 61,665 5991 (25.3)
Olanzapine N05AH03 NG - - 17,335 5389 (22.7)
Aripiprazole 1 N05AX12 AG - A 11,900 2711 (11.7)
Lithium N05AN01 - - - 8925 2175 (9.2)
Risperidone N05AX08 NG - I 16,080 1931 (8.1)
Clozapine N05AH02 NG - A 3375 1118 (4.7)
Zuclopenthixol N05AF05 AG - - 4475 815 (3.4)
Chlorprothixene N05AF03 - - - 15,785 689 (2.9)
Paliperidone N05AX13 - - - 1490 587 (2.5)
Haloperidol 1 N05AD01 AG - - 6290 532 (2.2)
Ziprasidone N05AE04 - - - 1145 474 (2.0)
Flupenthixol N05AF01 NG - - 4305 308 (1.3)
Perphenazine N05AB03 - - - 575 270 (1.1)
Amisulpride N05AL05 - - - 740 189 (<1)
Levomepromazine N05AA02 - - - 4605 136 (<1)
Pimozide N05AG02 AG - T-req 615 110 (<1)
See Table 1 for legend. Numbers in brackets are percentage expressed relative to total consumption of antipsychotics
in DDD. T-req = test required and I = informative. Drugs with a consumption of less of 100,000 DDD are not shown.
Table 4. Consumption of drug combinations having Clinical Pharmacogenetics Implementation
Consortium CPIC/Dutch Pharmacogenetics Working Group (DPWG) dosing guidelines.
Codeine Tramadol Metoprolol Amitriptyline
70,853 264,065 277,090 34,922
Duloxetine 1 30,405 1153 (355) 5544 (2126) 2596 (1399) 1825 * (592)
Fluoxetine 1 10,733 347/0.06 (127) 1102 * (443) 699 (409) 158 (77)
Paroxetine 1 12,881 341/0.06 (108) 1202 (441) 1203 (761) 183 * (82)
Sertraline 1 100,490 2644 (734) 11,221 (3962) 8014 (4156) 1496 * (582)
Data are presented as total no of users who redeemed the drugs shown either alone (upper and left panel) or in
combination during 2017. Numbers in brackets show total number of users who redeemed the drug combinations
on the same day. 1 Inhibitor of CYP2D6. Drug–drug interactions are scored by using MedScape [25]. Underlined:
monitor closely; bold: serious use alternate. All warnings are related to CYP2D6 activity except *. This warning
refers to increases in serotonin levels.
Table 5. Age distribution of consumption in terms of prevalence.
Sertraline Tramadol Metoprolol(S + T) (S + M) (S +T)/S
(S +
T)/T
(S +
M)/S
(S +
M)/M
Age Users/1000 Inhabitants (%)
00–19 4.0 2.3 0.6 0.1 0.0 1.3 2.3 0.4 2.3
20–29 20.2 18.9 2.3 0.9 0.1 4.5 4.8 0.7 6.1
30–39 23.1 34.1 5.4 1.8 0.3 7.6 5.2 1.4 5.7
40–49 22.3 49.8 18.3 2.4 0.8 10.7 4.8 3.8 4.6
50–59 19.5 62.9 47.7 2.6 1.5 13.3 4.1 7.8 3.2
60–69 18.2 76.4 106.4 2.8 2.7 15.5 3.7 14.6 2.5
70–79 20.6 92.5 161.9 3.7 4.0 18.0 4.0 19.6 2.5
80– 29.3 117.2 205.5 5.1 6.4 17.4 4.3 21.9 3.1
All 17.5 45.9 48.2 2.0 1.4 11.2 4.2 8.0 2.9
Left part of the Table: Age distribution of consumption expressed in terms of prevalence. (S + T): sertraline redeemed
in combination with tramadol; (S + M): sertraline redeemed in combination with metoprolol. “All” is the prevalence
across all age groups (bottom row). Right part of the table: prevalence in percentage of (S + T) and (S + M) relative
to (S) sertraline, (T) tramadol and (M) metoprolol.
J. Pers. Med. 2020, 10, 3 6 of 11J.  ers.  e .  ,  , x FOR PEER REVIEW    f  2 
 
 
Figure 1. Percentage of  total  consumption  in DDD  in 2017 of drugs having actionable guidelines 
(orange), non‐actionable guidelines (light brown), and no guideline (green) related to CYP2D6 and/or 
CYP2C19 for antidepressants (A), opioids (B), and antipsychotics (C). Numbers in brackets refer to 
the number of drugs in each category. 
Table  4.  Consumption  of  drug  combinations  having  Clinical  Pharmacogenetics  Implementation 
Consortium CPIC/Dutch Pharmacogenetics Working Group (DPWG) dosing guidelines. 
    Codeine  Tramadol  Metoprolol  Amitriptyline 
    70,853  264,065  277,090  34,922 
Duloxetine 1  30,405  1153 (355)  5544 (2126)  2596 (1399)  1825 * (592) 
Fluoxetine 1  10,733  347/0.06 (127)  1102 * (443)  699 (409)  158 (77) 
Paroxetine 1  12,881  341/0.06 (108)  1202 (441)  1203 (761)  183 * (82) 
Sertraline 1  100,490  2644 (734)  11,221 (3962)  8014 (4156)  1496 * (582) 
Data are presented as total no of users who redeemed the drugs shown either alone (upper and left 
panel)  or  in  combination  during  2017.  Numbers  in  brackets  show  total  number  of  users  who 
redeemed the drug combinations on the same day. 1 Inhibitor of CYP2D6. Drug–drug interactions are 
scored by using MedScape [25]. Underlined: monitor closely; bold: serious use alternate. All warnings 
are related to CYP2D6 activity except *. This warning refers to increases in serotonin levels. 
Figure 1. Percentage of total consumption in DDD in 2017 of drugs having actionable guidelines
(orange), non-actionable guideline (light brown), and o guideline ( reen) related to CYP2D6 and/or
CYP2C19 f r antidepressants (A), opioids (B), a d tipsychotics (C). Numbers in brackets refer to the
number of d ugs in each category.
3. Results
In 2017 in Den ark 49 drugs corresponding to 469.1 million DDD had CPIC/DPWG guidelines
(both AG and N-AG) for CYP2D6 and/or CYP2C19 drug gene pair’s equivalent to 14.5% of the total sale
in DDD. Of these, 28 drugs have AG corresponding to 375.2 million DDD i.e., 80.0% of total consumption
in DDD of drugs having both AG and N-AG. Fifty-eight percent of the consumption in DDD of drugs
having AG was within the ATC codes of A02BC (proton pump inhibitors— pantoprazole (61.3 million
DDD, 312,000 sers), lansoprazole ( 3.6 million DDD, 146,000 users), and omeprazole 3 .1 million DDD,
130,480 users)); B01AC (platelet aggregation inhibitors excluding heparin—clopidogrel (36.8 million
DDD, 120,000 users)); and C 7AB (beta blocking agents— metoprolol (47.7 million DDD, 77,660 users)).
Most of the gui elines i term of number, both AG and N-AG, exist within the ATC codes
N06A (antidepressants drugs), N02A (opioids) includ g codeine (R05DA04), and N05A (antipsychotic
drugs). Due to this, the consumption of drugs withi these AT codes in DDD and number of users
who redeemed the drugs were further scrutinized. The total consumption in 2017 were 157.0, 48.9,
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and 23.7 million DDD for antidepressants, opioids, and antipsychotics, respectively (Figure 1A–C).
The consumption of drugs having AG constituted 78.6% and 57.5% of the total consumption in DDD
for antidepressants and opioids, which corresponds to the consumption of 11 and 3 different drugs,
respectively (see also Tables 1 and 2). The same numbers for antipsychotic drugs were 17.6% for the
consumption of four drugs.
Tables 1–3 show the total consumption in DDD of antidepressants, opioids, and antipsychotics in
increasing order as well as number of users who redeemed the drugs. Note that the numbers of users
for the different drugs shown are not additive, since dispensing to the same users can occur for the
different drugs. The Tables also give an overview of drugs having both actionable-, non-actionable-
and no-guidelines at all, as well as drugs having FDA approved annotations in their drug labels
containing PGx information for CYP2D6 and CYP2C19 drug–gene pairs. Moreover, drugs known to be
inhibitors of CYP2D6 or CYP2C19 [30] are also marked. For antidepressants sertraline, citalopram, and
venlafaxine (Table 1) both in terms of DDD and number of users were the most redeemed drugs. The
consumption of these three drugs constituted approximately 50% of total consumption of DDD in this
drug class and they all have AG and, for citalopram and venlafaxine, FDA annotations as well.
For analgesics (Table 2), the consumption of opioids including codeine in DDD constituted 24.8%
of the total consumption of analgesics. Both tramadol and codeine have AG and FDA annotations and
the consumption of these drugs in both DDD and number of users constituted more than 50% of total
consumption of opioids. Since the content of codeine in N2AJ06 equals that of codeine (R05DA04) i.e.,
25 mg, opposite N02AJ07 where the content is three times less, the notion AG and FDA annotation was
added to this combination of codeine and paracetamol.
In case of antipsychotic drugs (Table 3) the total consumption in DDD and users is somewhat less
compared to opioids and antidepressants and only four drugs out of 24 drugs have AG (Table 3 shows
16 drugs. See legend to Table), however, the highest prevalence of non-AG exists within this drug class.
Additionally, in this class of drugs, the annotation “test required” is seen for pimozide. Ariprazole is
the most selling drug having both and AG and FDA annotation. For most, but not all, of the drugs
shown in the tables there is a good match between those having AG and FDA annotations.
Table 4 shows the number of users who redeemed on the same day or during 2017, a combination
of drugs (antidepressants) known as inhibitors of CYP2D6 [30] together with either codeine, tramadol,
metoprolol, or amitriptyline. All drugs in the table have AG. From the table it can be seen that e.g.,
264,065 users redeemed tramadol, 30,405 users redeemed duloxetine, and 5,544 users redeemed the
combination of tramadol and duloxetine during 2017, and 2,126 redeemed the combination on the same
day. It can be calculated from the table that users who redeemed the combinations of drugs on the same
day as percentage of the whole year ranged from 27.8% for the combination of sertraline and codeine
to 63.3% for paroxetine and metoprolol with a median value of 41.7%. The highest prevalence’s for
combinations were seen for sertraline in combination with tramadol or metoprolol for both the same
day and the whole year. By using the drug interaction tracker provided by Medscape [25] the aim was
to visualize warnings “monitor closely” and “serious use alternate” for different drug combinations
shown. Most of the drug combinations in the Table 4 were scored by the tracker as either “monitor
closely” or “serious use alternate” in relation to CYP2D6.
Table 5 shows age-distribution expressed as prevalence of users who redeemed tramadol,
metoprolol and sertraline either alone or in combination during 2017. The prevalence of tramadol
and metoprolol redeemed alone or in combination with sertraline ((S + T) and (S + M)) increased as
function of increasing age intervals with the highest prevalence seen for 80+ years. The prevalence of
sertraline varies around 18–22 for most age intervals with the highest prevalence seen for 80+ years.
The Table also shows (right part) the prevalence of sertraline in combination with tramadol (S + T) or in
combination with metoprolol (S + M) expressed relative to the prevalence of sertraline, tramadol and
metoprolol. As seen, the relative prevalence of S + T and S + M when expressed relative to sertraline
increases as function of age intervals, whereas the relative prevalence of S + T and S + M relative to
tramadol and metoprolol did not vary much across age intervals.
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4. Discussion
This study visualizes the drug consumption in Denmark in 2017 for drugs having CPIC and/or
DPWG dosing guidelines and FDA annotations and suggests future directions, especially with focus on
vulnerable polypharmacy patients. Pharmacogenomics based prescribing is one of the first applications
of genomics in medicine [21] and testing of polymorphism of genes encoding CYP450 enzymes
and in particular CYP2D6 and CYP2C19, but also CYP2C9 has the potential to be a valuable tool
to optimize prescribing, dosing, and monitoring by identifying phenotype status [17–19,31] and to
reduce re-hospitalization in polypharmacy patients [32]. However, significant barriers still exist
mainly concerning physicians´ and pharmacists´ awareness and education, and question marks about
evidence levels and significance are brought into the discussions. In Denmark the situation does not
look much different and the use of PGx tests have not gained foothold in daily clinical practice [22]
mainly because of significant organizational barriers and lack of evidence. It has been estimated that
around 750,000 Danes are polypharmacy users defined as taking ≥5 drugs corresponding to 13% of the
Danish population and for 75+ years, 54% of this age group are polypharmacy users [32]. Taken the
average Caucasian frequencies of DGI recently reported [31] for CYP2D6 (UM 4.1%, IM 6.2%, and PM
5.4%) and for CYP2C19 (UM 31.5%, 26.9%, and PM 2.6%) into consideration further suggests that a
significant proportion of the Danish population will have phenotypes for which actions in principle
should be taken regarding dose adjustments or avoidance of the given drugs. By using the above
numbers, which are in alignment with other reported prevalence’s [33], it can roughly be estimated
that approximately 0.9 million of the total Danish population of 575 million will be either UM, IM,
or PM for CYP2D6 and approximately 3.5 million for CYP2C19, and for polypharmacy users the
numbers are approximately 0.1 and 0.5 million, respectively, of which the elderly constitutes 50% (see
above). Medication reviews performed in two Danish nursing homes, of which all residents were
polypharmacy users, revealed that 80% of the residents were administered drugs for which there exists
AG (unpublished results). This underscores the findings of this study showing that a large portion
of the Danish population, in particular the elderly, has been or will be exposed to one or more drugs
having AG. Citalopram, clopidogrel, lansoprazole, omeprazole, pantoprazole, and sertraline were each
redeemed to more than 100,000 users, and metoprolol and tramadol to more than 250,000 users. For
example, the dosing guidelines for tramadol (https://www.pharmgkb.org) alert to an action to be taken
for CYP2D6 IM, PM, or UM metabolizers, and based on the above frequencies for UM, IM, and PM
for CYP2D6 approximately 41,000 of the 265,030 users who redeemed tramadol could potentially be
considered for an action to be taken.
In spite of that a large number of antipsychotic drug are metabolized by CYP2D6 and CYP2C19,
only a very few have AG and FDA annotations, with aripiprazol as the most redeemed (11,900 users)
drug with an AG. However, due to the complexity of dosing antipsychotic drugs several dosing models
based on PGx testing (among others) have been proposed [34,35].
The publically available drug-interaction checker provided by MedScape, used in this study to
score for severity of DDI, showed that for the drug combinations investigated, mostly all had warnings
related to inhibition of CYP2D6 activity by duloxetine, fluoxetine, paroxetine, and sertraline. The
number of users affected by the warning “serious use alternate” seem to be relatively low compared
to the number of user affected by the warning “monitor closely”. Surprisingly, the fraction of drug
users who redeemed the drug combinations investigated for on the same day seem to be relative
high (median value of 41.7%) compared to the whole year. Personal experiences from the pharmacy
practice is, that the warning “monitor closely” is very seldom taken into consideration unless the
user has undergone a medication review. The warning “serious use alternate”, if caught, is in
principle simpler to handle due to the clear message of action. However, independently of the drug
combinations are redeemed on the same day or during the same year, actions can only be taken if
it is brought to the attention of the pharmacist and physician. This study does not provide data on
how many unwanted drug combinations that have been captured during the dispensing process.
If the impact of being scored as PM or UM is also taken into consideration, the balance between
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“monitor closely” and “serious use alternate” might change significantly towards the latter, which
recently has been substantiated for opioids [17,36] and for metoprolol [37]. It should be mentioned
that other drug-interaction checkers might score the warnings shown in Table 5 differently from
that obtained in this study, e.g., “Interaktionsdatabasen” provided by the Danish Medicines Agency
(http://www.interaktionsdatabasen.dk/); however, it is the author’s opinion that the principles outlined
above still will be valid.
The increased prevalence’s of tramadol and metoprolol redeemed alone or in combination with
sertraline as function of age intervals seen in this study support the notion that elderly people are more
exposed to inappropriate polypharmacy than younger people are [38]. The term “used or redeemed
alone” in this study does not exclude that users could have redeemed other drug combinations not
looked for. The prevalence’s of sertraline in combination with tramadol (S + T) or in combination with
metoprolol (S + M) expressed relative to the prevalence of sertraline, tramadol, and metoprolol alone
(Table 5) suggests that the fraction of sertraline users who get tramadol or metoprolol increases as a
function of age. The opposite is found when expressed as relative to the prevalence of tramadol or
metoprolol, as the fraction of metoprolol and tramadol users getting sertraline is constant across age
intervals. The same pattern was seen for duloxetine in combination with tramadol and metoprolol
(results not shown). In conclusion, the limitations of this register study are that the numbers of users
who redeemed the drugs searched for in this publication does not provide any information about
dose, compliance, and clinical effects, as well as duration of treatments. However, the findings of this
exploratory register study clearly showed that a large fraction of the Danish population, especially
the elderly part, are exposed to drugs or drug combinations for which there exist dosing guidelines
provided by CPIC or DPWG as well as FDA annotation related to PGx of CYP2D6 and CYP2C19.
This underscores the importance of accessing and accounting for DDI, DGI, and DDGI, focusing on
the elderly vulnerably (e.g., those in nursing homes) in the first place, while understanding that it is
a complex process demanding multidisciplinary collaborations to obtain infrastructural capacities
for good decision-making processes, as well as further studies to assess the economic impact of
pre-emptive PGx-panel testing.
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